Last Updated: 2011-11-18 12:12:20 -0400 (Reuters Health)
By Alina Selyukh and Anna Yukhananov
WASHINGTON (Reuters) - U.S. drug regulators on Friday withdrew approval of Roche's Avastin as a treatment for breast cancer, capping a protracted and emotional battle over a drug backed by many survivors of the disease.
U.S. Food and Drug Administration Commissioner Margaret Hamburg said Avastin has not proven safe and effective for breast cancer. The drug will remain on the market for other uses, such as treating types of colon, lung, kidney and brain cancer.
Advisers to the FDA paved the way for Friday's decision, recommending against Avastin's use in breast cancer in June. The panel, convened after Roche appealed the FDA's original plan to revoke the breast cancer indication, heard emotional testimony from patients who insisted that Avastin had saved their lives.
Some insurers have already started pulling back on Avastin coverage for breast cancer. Without FDA approval, women worry they will not have access to the expensive drug.
Using Avastin for metastatic breast cancer costs about $88,000 a year, based on patients taking it for 11.3 months, Roche said.
The Medicare federal insurance program for the elderly and disabled will continue paying for Avastin for breast cancer, despite the FDA decision, a spokesman said.
"Medicare will continue to cover Avastin," said Don McLeod, spokesman for the Centers for Medicare and Medicaid. "CMS will monitor the issue and evaluate coverage options as a result of action by the FDA but has no immediate plans to change coverage policies."
"We are disappointed with this outcome," said Charlotte Arnold, a spokeswoman for Genentech, a unit of Roche. "We remain committed to the many women with this incurable disease and will continue to provide help through our patient support programs to those who may be facing obstacles to receiving their treatment."
She said Roche will pursue a new Phase III study of Avastin in combination with the chemotherapy drug paclitaxel in previously untreated metastatic breast cancer.
The FDA's decision could prompt a review of industry guidelines from groups like the National Comprehensive Cancer Network, which represents leading cancer treatment centers.
NCCN has so far not strayed from its earlier guideline, approving use of Avastin with paclitaxel for some patients.
Copyright © 2011 Reuters Limited. All rights reserved.Republication or redistribution of Reuters content, including by framing orsimilar means, is expressly prohibited without the prior written consent ofReuters. Reuters shall not be liable for any errors or delays in thecontent, or for any actions taken in reliance thereon.Reuters and the Reuters sphere logo are registered trademarks andtrademarks of the Reuters group of companies around the world.